Fracture Rates In Radium223 (Ra223) Treated Mcrpc Patients (Pts): A Real-World Analysis In 177 Pts Treated At A Single Community Center 2010-2018

Yen Thi Kim Hong Cao,Michael Elias,Janson Trieu,Vanessa Rojas,Michael J. Anderson,Nicholas J. Vogelzang

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 0|浏览5

暂无评分

摘要

41Background: Ra223 was FDA approved 5/15/13 as a life extending therapy in conjunction with Standard of Care (SOC) agents for mCRPC in the ALSYMPCA trial. However, agents such as abiraterone (abi)...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要